At St. Clair Health, a community health system in Pittsburgh, where Dr. Pray was working to build up an organized heart ...

Prothena Corporation’s Phase III AFFIRM-AL trial of birtamimab in individuals with amyloid light-chain (AL) amyloidosis ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the ...

Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Prothena (PRTA) stock drops as a late-stage trial for the company's lead candidate fails, prompting Oppenheimer and Jefferies ...

Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for ...

Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the ...

Accelerated diagnoses, diversified pipelines, regulatory convergence, strategic partnerships, value-based access models, and ...

The Chattanooga Heart Institute at CHI Memorial announced the opening a new center aimed at detecting and treating an often ...